These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Correlations between multiple sclerosis functional composite, expanded disability status scale and health-related quality of life during and after treatment of relapses in patients with multiple sclerosis. Ozakbas S; Cagiran I; Ormeci B; Idiman E J Neurol Sci; 2004 Mar; 218(1-2):3-7. PubMed ID: 14759626 [TBL] [Abstract][Full Text] [Related]
3. Reconsidering clinical outcomes in Multiple Sclerosis: relapses, impairment, disability and beyond. D'Souza M; Kappos L; Czaplinski A J Neurol Sci; 2008 Nov; 274(1-2):76-9. PubMed ID: 18817932 [TBL] [Abstract][Full Text] [Related]
5. You get what you measure: evaluating endpoints in MS clinical trials. Marrie RA Neurology; 2008 Aug; 71(9):620-1. PubMed ID: 18685132 [No Abstract] [Full Text] [Related]
6. MRI as an outcome in multiple sclerosis clinical trials. Daumer M; Neuhaus A; Morrissey S; Hintzen R; Ebers GC Neurology; 2009 Feb; 72(8):705-11. PubMed ID: 19073945 [TBL] [Abstract][Full Text] [Related]
7. Fampridine-SR for multiple sclerosis and spinal cord injury. Hayes KC Expert Rev Neurother; 2007 May; 7(5):453-61. PubMed ID: 17492896 [TBL] [Abstract][Full Text] [Related]
9. Azathioprine and methotrexate in multiple sclerosis. Fernández O; Fernández V; De Ramón E J Neurol Sci; 2004 Aug; 223(1):29-34. PubMed ID: 15261557 [TBL] [Abstract][Full Text] [Related]
10. Reply to "Motor assessment of upper extremity function and its relation with fatigue, cognitive function and quality of life in multiple sclerosis patients". Padua L; Nociti V; Bartalini S; Patti F; Quattrone A; Tonali P; Ulivelli M; Valentino P; Zappia M; Batocchi AP J Neurol Sci; 2007 Feb; 253(1-2):106. PubMed ID: 17215006 [No Abstract] [Full Text] [Related]
11. Magnetic resonance imaging metrics and their correlation with clinical outcomes in multiple sclerosis: a review of the literature and future perspectives. Bar-Zohar D; Agosta F; Goldstaub D; Filippi M Mult Scler; 2008 Jul; 14(6):719-27. PubMed ID: 18424478 [TBL] [Abstract][Full Text] [Related]
13. Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis. Baier ML; Cutter GR; Rudick RA; Miller D; Cohen JA; Weinstock-Guttman B; Mass M; Balcer LJ Neurology; 2005 Mar; 64(6):992-5. PubMed ID: 15781814 [TBL] [Abstract][Full Text] [Related]
14. Use of interferon-beta in the treatment of multiple sclerosis. Derwenskus J; Lublin FD Adv Neurol; 2006; 98():257-71. PubMed ID: 16400838 [No Abstract] [Full Text] [Related]
15. MRI as an outcome in multiple sclerosis clinical trials. Tenser RB Neurology; 2009 Dec; 73(22):1933-4; author reply 1934. PubMed ID: 19949044 [No Abstract] [Full Text] [Related]
16. Early treatment of multiple sclerosis to prevent neurologic damage. Coyle PK Neurology; 2008 Dec; 71(24 Suppl 3):S3-7. PubMed ID: 19064872 [TBL] [Abstract][Full Text] [Related]
17. [Evaluation and multiple sclerosis]. Béthoux F Ann Readapt Med Phys; 2005 Jul; 48(6):369-75. PubMed ID: 15963830 [TBL] [Abstract][Full Text] [Related]
18. Difference between generic and multiple sclerosis-specific quality of life instruments regarding the assessment of treatment efficacy. Ozakbas S; Akdede BB; Kösehasanogullari G; Aksan O; Idiman E J Neurol Sci; 2007 May; 256(1-2):30-4. PubMed ID: 17379247 [TBL] [Abstract][Full Text] [Related]
19. Relapse, remission, and progression in multiple sclerosis. McDonald WI N Engl J Med; 2000 Nov; 343(20):1486-7. PubMed ID: 11078776 [No Abstract] [Full Text] [Related]
20. How much can we learn from long-term extension trials in multiple sclerosis? Noseworthy JH Neurology; 2006 Sep; 67(6):930-1. PubMed ID: 17000954 [No Abstract] [Full Text] [Related] [Next] [New Search]